北京大学第一医院肾内科是我国肾脏病事业奠基人王叔咸教授在上世纪50年代建立的中国第一个肾脏病专业。在王海燕教授带领下，科室不断发展壮大，1992年成为卫生部肾脏疾病重点实验室，2007年和2008年为教育部重点学科及创新团队，2010年至今是国家自然科学基金委创新群体，2011年评为慢性肾脏病防治教育部重点实验室。赵明辉教授领导肾科于2017年入选北京大学双一流建设学科。在中国最佳医院、医院科技和临床影响力三个排行榜中均在本学科排名第一。

　　本学科利用患者肾活检标本为核心的临床资源数据库及多学科技术平台，形成3个主要研究方向：阐明慢性肾脏病（CKD）发生发展的危险因素和遗传背景；探讨我国CKD常见肾脏病的发病机制；通过循证研究提出适合我国国情的CKD防治策略。近年来以提高肾脏病的临床医疗水平为出发点，以疑难重症肾脏病诊疗及CKD进展防治为主线，依托跨学科研究及学术交流，在肾脏病的流行病学、遗传背景、病理生理、免疫炎症机制、肾脏病慢性进展的防治及机理和循证治疗等方面开展深入研究。在CKD的流行病学、肾小球疾病免疫炎症、IgA肾病的循证治疗和遗传背景等部分领域达到国际先进水平，成为全面发展的国内肾脏病领域主要领军单位之一，业已在国际肾脏病学领域占有一席之地。

　　学科一直保持稳定并稳健发展，目前拥有医生及研究人员52名（博士49名），技术及管理人员16人。其中正高职13名（博导9名），副高职16名。拥有长江学者1名，国家自然科学基金委杰出青年4名、优秀青年2名，科技北京百名领军人才1名，教育部新世纪人才7人，北京市科技新星5人。是一支充满无限活力的研究队伍。

　　目前本学科拥有2个病房（75张病床），以及2个血液透析中心（100台透析机）、腹膜透析中心、危重肾脏病监护室、病理室、临床检验室、B超室等临床部门。建立起按病种分类的长期随访门诊，包括肾小球病、IgA肾病、自身免疫性肾损害（血管炎肾损害、狼疮性肾炎、抗基底膜病）、肾小管间质病、CKD门诊、遗传性肾脏病、透析前门诊、血管通路门诊等。通过普通门诊－病房－随访门诊－透析中心的一体化流程，为肾脏病患者提供全方位的诊治和随访服务，显著改善患者病情和生活质量。全年门诊量超过11万例次。此外作为开放实验室，建有免疫室、分子和遗传室、细胞室等，拥有数千万的较为先进的实验仪器，基本满足各种实验条件，实现“临床－实验室－临床”的转化医学研究。曾获得获国家科技进步二等奖、教育部自然科学奖一等奖等多种奖项。

　　主持完成中国成年住院患者急性肾损伤（AKI）首次多中心调查，确定AKI发病率，40%患者进展至CKD。发现我国糖尿病相关CKD患者患病率逐渐增高的趋势。主导完成激素治疗IgA肾病的国际多中心临床试验。阐明补体旁路途径活化参与血管炎的机制及其预后相关的HLA基因位点。阐明IgA1分子糖基化缺陷、补体系统参与IgA肾病的机制。通过确定自噬通路在SLE发病的作用，提出自噬参与SLE发病易感性的假说。阐明了抗基底膜（GBM）抗体免疫学特性变化、GBM自身抗原分子内抗原表位扩展及其与抗GBM抗体结合的主要部位，提出抗IV型胶原α5链自身抗体在Goodpasture病中的致病性。阐明了马兜铃酸肾病的疾病谱和临床转归及肾损伤分子-1、Na/K-ATP酶参与肾脏病进展的机制，建立了尿生物学标志物检测体系。

 

　　机构负责人：赵明辉

　　联系人：孟立强

　　邮箱：mhzhao@bjmu.edu.cn

　　电话：010-83572550

　　地址：北京市西什库大街8号北京大学第一医院实验中心（科研楼）3层

　　网站：http://www.pkufh.com/Html/Departments/Main/Index_308.html

 

　　　　Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education

　　The Renal Division of Peking University First Hospital is the first Chinese nephrology Division that established in the 1950s by the founder of Chinese Nephrology, Professor Shu-xian Wang. In the 1980s, under the leadership of Prof. Hai-yan Wang, our division has been developing substantially. It has been crowned as the key laboratory of Renal disease of the Ministry of Health in 1992, as the key discipline and the innovation team of the Ministry of education in 2007 and 2008, respectively, the innovative group of National Natural Science Foundation of China since 2010, and the key laboratory of CKD prevention and treatment of the Ministry of Education in 2011. It was honorably known as the discipline that was one of the double first-class constructions of Peking University under the administrative management of Professor Ming-hui Zhao. The division has been ranked as No 1 consecutively in several ranking systems in China, including Fudan version of the best clinical discipline, the prestigious research as well as the clinical influence in China.

　　Based on multidisciplinary technological platform and the database of clinical cohorts, our division has been focusing on three main directions of scientific research:

　　1．To investigate the pathogenesis of common kidney diseases of CKD;

　　2. To identify the risk factors and genetic background in developing and progression of CKD;

　　3．To develop prevention and treatment strategies of CKD in China using evidence-based research.

　　In recent years, aiming to improve capacity of clinical service, focusing on the diagnosis and treatment of complicated and severe kidney diseases, developing prevention and treatment strategy of CKD, we have performed cutting edge academic research in CKD epidemiology, genetic background, renal pathophysiology, immune-inflammatory pathogenesis and evidence-based treatment of kidney diseases with international reputation. Renal Division of Peking University First Hospital is recognized as one of the tope ranked renal program in the world.

　　Our division has been keeping fast pace of stable and steady development; we have 52 nephrologists and physician-scientists, 16 technical and administration staffs. Among the nephrologists and physician-scientists, there are 13 full professors and 16 associated professors. One is the Yangtze-river scholars, 4 have been awarded as outstanding youth of national natural science foundation of China (NSFC), 2 as the young outstanding youth of national NSCF, 1 has been crowned as one of hundred talented Science and Technology in Beijing, 7 have been ranked as the new century talents pioneers of Ministry of Education, 5 have been awarded as Beijing nova of municipal science and technology. Our renal program has been recognized as a young, passionate and dynamic one.

　　At present, our division includes two nephrology wards (75 beds), two hemodialysis centers (100 dialysis machines), a peritoneal dialysis center with 370 CAPD patients, an intensive care unit with 6 beds, a pathology laboratory, a clinical laboratory and a ultrasonic team. We have established long-term follow-up clinics according to various clinical cohorts, including common glomerular disease, IgA nephropathy, autoimmune renal diseases (ANCA-associated vasculitis, lupus nephritis, anti-GBM disease), tubulointerstitial disease, CKD, hereditary kidney disease, pre-dialysis clinics, vascular access clinic etc. Through the integration of nephrology wards and follow up clinics, we provide a full range of diagnosis, treatment and follow-up services for patients with kidney disease, which somehow significantly improved the patient's health condition and quality of life. Our division has more than 110 thousand outpatients visits annually. In addition, as an open laboratory, we provide research platforms on renal immunology, molecular genetics, histopathology, cellular biology etc. In our research laboratory, we have advanced experimental instruments that could meet the need of most translational research. We have won a great number of awards such as the second prize for national scientific and technological progress, the first prize in the natural science award of the Ministry of Education.

　　We conducted the first national multi-center survey of acute kidney injury (AKI) among adult inpatients in China, we revealed the incidence of AKI and found that 40% of the AKI patients progressed to CKD. We discovered the surging prevalence of diabetic kidney disease (DKD) in China. We just accomplished the first-stage of an international multi-center clinical trial on steroid therapy in patients with IgA nephropathy. We have identified pathogenic role of complement alternative pathway activation played and HLA susceptibility in ANCA-associated vasculitis. We have revealed the role of deglycosylated IgA1 molecule and complement activation in IgA nephropathy. By determining the role of autophagy pathway in SLE, autophagy in the susceptibility of SLE is proposed. We have elucidated the fine epitope and epitope spreading of anti-GBM disease and identified human alpha 5 chain as a novel autoantigen of anti-GBM disease. We have revealed the disease spectrum and clinical outcomes of aristolochic acid nephropathy, and established urinary biomarkers for tubule-interstitial kidney diseases.   

 

　　Chief of Renal Division, Peking University First Hospital: Prof. Ming-hui Zhao

　　Contacts: Dr. Li-qiang Meng

　　Email address: mhzhao@bjmu.edu.cn

　　Telephone: 010-83572388

　　Address: 3rd Floor, Experimental Lab Center , Peking University First Hospital, 8 Xishiku St., Xicheng District, Beijing 100034, P.R.China 

　　Website: http://www.pkufh.com/Html/Departments/Main/Index_308.html